Travecta Therapeutics

Travecta Therapeutics, established in 2017, is a biotechnology company headquartered in Singapore with an additional office in New York. It specializes in developing innovative pharmaceutical technologies for delivering therapeutic agents to the brain. The company's core platform, mVECTA, is built on a deep understanding of the MFSD2a transporter protein and its role in the blood-brain barrier. Travecta offers services such as Blood Drain Barrier Challenge and Breakthrough Discovery of MSFD2A Transport, along with its proprietary medicinal chemistry capabilities. The company partners with pharmaceutical firms to help overcome blood-brain barrier challenges, providing feasibility studies that generate in vitro and in vivo transport data using Travecta's proprietary models.